

EMADOC-1700519818-1860477

European Medicines Agency decision

EMA-003502-PIP02-24

of 28 January 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mezagitamab, in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA-003502-PIP02-24

of 28 January 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mezagitamab, in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Takeda Pharmaceuticals International AG on 17 January 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 December 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation for mezagitamab, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for mezagitamab, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for mezagitamab, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Takeda Pharmaceuticals International AG, Block 2 Miesian Plaza, 50-58 Baggot Street Lower, Dublin - 2 D02 HW68, Ireland.

EMADOC-1700519818-1694774
Amsterdam, 13 December 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003502-PIP02-24

Scope of the application

Active substance(s):

Mezagitamab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of primary immunoglobulin A nephropathy

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Takeda Pharmaceuticals International AG Ireland Branch

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Takeda Pharmaceuticals International AG Ireland Branch submitted for agreement to the European Medicines Agency on 17 January 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 26 February 2024.

Supplementary information was provided by the applicant on 06 September 2024. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of primary immunoglobulin A nephropathy

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection; subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of primary immunoglobulin A nephropathy

2.1.1. Indication(s) targeted by the PIP

Treatment of primary immunoglobulin A nephropathy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1: Open-label, single-arm trial to evaluate pharmacokinetics, safety and efficacy of mezagitamab in children from 2 years to less than 18 years of age with IgA nephropathy (IgAN)
Modelling and simulation analyses	Study 2: Modelling and simulation analyses (population pharmacokinetic (PopPK) and pharmacokinetic pharmacodynamic (PK/PD) models) to predict paediatric doses to be used in children from 2 years to less than 18 years of age with IgA nephropathy (IgAN)

Other studies	Not applicable
Extrapolation plan	Studies 1 and 2 are part of an extrapolation plan covering the paediatric population from 2 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2036
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.